Nonmuscle invasive bladder cancer: a primer on immunotherapy

12Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer.

Cite

CITATION STYLE

APA

Maruf, M., Brancato, S. J., & Agarwal, P. K. (2016, June 1). Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biology and Medicine. Cancer Biology and Medicine. https://doi.org/10.20892/j.issn.2095-3941.2016.0020

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free